Hypothesis

Individuals carrying the CRY1 gain-of-function variant require higher-intensity morning blue light (≥30 lux at 460‑480 nm) to achieve the same circadian phase advance and metabolic improvement as wild‑type carriers, because the variant reduces the efficacy of melanopsin‑driven SCN signaling to autonomic outputs that regulate hepatic glucose homeostasis.

Mechanistic Rationale

Melanopsin-containing retinal ganglion cells (ipRGCs) send glutamatergic projections to the suprachiasmatic nucleus (SCN) and also to the paraventricular nucleus (PVN), driving sympathetic tone that influences hepatic gluconeogenesis via the splanchnic nerve. CRY1 stabilizes the negative feedback loop within SCN neurons, shortening the period and dampening the amplitude of Per transcription. A gain‑of‑function CRY1 allele is predicted to increase the threshold for light‑induced Ca²⁺ influx in ipRGCs needed to overcome this enhanced repression, thereby shifting the dose‑response curve for SCN activation rightward. Consequently, the same photon flux yields less PVN‑medi sympathetic activation and weaker suppression of hepatic glucose production.

Testable Predictions

1. Melatonin onset advance after a fixed 30‑minute morning blue‑light exposure will be significantly smaller in CRY1 variant carriers than in non‑carriers at 10 lux, but will equalize at 60 lux.
2. Hepatic insulin sensitivity, measured by the Matsuda index from an oral glucose tolerance test, will improve post‑exposure only when the light intensity exceeds the genotype‑specific threshold.
3. fMRI BOLD signal in the SCN and PVN will show a lower slope of activation versus light intensity in variant carriers.

Experimental Design

• Recruit 60 healthy adults stratified by CRY1 genotype (20 homozygous variant, 20 heterozygous, 20 wild‑type).
• In a crossover protocol, each participant receives three morning light conditions (10 lux, 30 lux, 100 lux of 470 nm LED) separated by ≥1 week washout.
• Light exposure: 30 minutes, starting 30 minutes after habitual wake time, administered via a Ganzfeld dome.
• Outcomes collected each session: salivary melatonin every 20 minutes from −60 to +120 minutes relative to exposure, SCN/PVN fMRI during a 5‑minute light pulse, and a 2‑hour oral glucose tolerance test beginning at +90 minutes.
• Primary analysis: mixed‑effects model testing genotype × light‑intensity interaction on melatonin phase shift and Matsuda index.

Potential Implications

If confirmed, this hypothesis would provide a mechanistic basis for personalized phototherapy: prescribing intensity‑tailored morning blue light based on CRY1 (and potentially PER3) genotype to optimize circadian alignment and metabolic health in shift‑propensity populations, jet‑lag recovery, and preventive cardiometabolic care.